An advisory committee to the FDA said the agency should approve Pfizer Inc.'s drug axitinib for use in patients with advanced kidney cancer.
WSJ.com: What's News US, Wall Street Journal
Wed, 12/07/2011 - 9:59am
An advisory committee to the FDA said the agency should approve Pfizer Inc.'s drug axitinib for use in patients with advanced kidney cancer.